RNA oligonucleotide as a novel replacement and improvement over in vitro transcribed mRNA for personalized cancer vaccines.
20 Nov 2024
New Modalities
- The need to increase the number of neoantigens in certain personalized cancer vaccines
- Advantages and drawbacks of IVT-derived mRNA/LNP compared to other modalities such as peptides or RNA oligonucleotides
- Economic constraints in the highly diverse RNA oligonucleotide synthesis process
- On-demand manufacturing of oligonucleotides under GMP conditions
Industry Expert
